Health TrialsbyHealthPanel

Study of Bronchiectasis and Associated Cardiovascular Comorbidities

ConditionBronchiectasis
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-80
SponsorAssiut University

About this trial

Effect of cardiovascular comorbidities on disease severity and quality of life in Patients with acute exacerbation of non-cystic fibrosis bronchiectasis

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

None

Disqualifiers

Any Patients who refuse to participate in the study.

Any other comorbidity or end-organ failure may affect the study's result.

Trial population

all patients at the study period attending the chest department at Assuit university

Trial design

Design model

Case-control

Time perspective

Cross-sectional

Treatments tested in this trial

  • Echocardiography

    Device

    echocardiographic study of both groups

Treatment groups

30 Participants
are divided into 2 treatment groups
Group A: Patient with bronchiectasis and cardiovascular comorbidities1 intervention
Group B: Patients with bronchiectasis and without cardiovascular comorbidities1 intervention

Trial outcomes

Primary outcomes

1

assessment of BNP (Brain natriuretic peptide) pg/ml levels in patients with bronchiectasis and cardiovascular comorbidities.

Serum BNP (Brain natriuretic peptide) pg/ml will be compared in both groups.

Time frame
March 2023 to September 2023
2

Assessment of Quality of life in patients and control groups using The Short Form (36) Health Survey (SF-36)

The Short Form (36) Health Survey will be performed in both groups. The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability.

Time frame
March 2023 to September 2023

Secondary outcomes

1

Hospitalization frequency in patient group compared to control group.

Number of hospital admission in the last year will be compared in both groups.

Time frame
March 2023 to September 2023

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Assiut University

Lead sponsor

Aliae AR Mohamed Hussein [ahussein

Collaborator

Source ClinicalTrials.gov
Apply now